At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAZE Maze Therapeutics
Pre-Mkt 06-23 06:56:33 EDT
25.57
-0.11
-0.43%
盘前26.11
+0.54+2.11%
04:00 EDT
High26.03Low25.34Vol530.34K
Open25.69D1 Closing25.68Amplitude2.67%
Mkt Cap1.41BTradable Cap849.91MTotal Shares55.25M
T/O13.60MT/O Rate1.60%Tradable Shares33.24M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)
TIPRANKS  ·  06-22 18:46
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor
TIPRANKS  ·  06-11
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor
Maze Therapeutics shareholders elect Coloma, Kumar as directors at annual meeting
Reuters  ·  06-11
Maze Therapeutics shareholders elect Coloma, Kumar as directors at annual meeting
Maze Therapeutics CEO Jason V. Coloma sells 6,643 shares worth $174,171.83
Reuters  ·  06-04
Maze Therapeutics CEO Jason V. Coloma sells 6,643 shares worth $174,171.83
Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of common shares worth $381,499.47
Reuters  ·  06-04
Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of common shares worth $381,499.47
Maze Therapeutics posts corporate presentation on genetics-driven kidney, metabolic disease drug pipeline
Reuters  ·  06-03
Maze Therapeutics posts corporate presentation on genetics-driven kidney, metabolic disease drug pipeline
Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares for $197,554‬
Reuters  ·  06-03
Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares for $197,554‬
Maze Therapeutics CEO Jason V. Coloma disposes of 32,564 common shares worth $846,980.45
Reuters  ·  05-28
Maze Therapeutics CEO Jason V. Coloma disposes of 32,564 common shares worth $846,980.45
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
GlobeNewswire  ·  05-27
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
J.P. Morgan Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)
TIPRANKS  ·  05-23
J.P. Morgan Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics CFO Expands Role Amid Finance Leadership Change
TIPRANKS  ·  05-23
Maze Therapeutics CFO Expands Role Amid Finance Leadership Change
Maze Therapeutics SVP Finance Amy Bachrodt resigns, effective June 1
Reuters  ·  05-23
Maze Therapeutics SVP Finance Amy Bachrodt resigns, effective June 1
Maze CEO Jason Coloma disposes 1,938 Maze Therapeutics shares worth $50,388
Reuters  ·  05-19
Maze CEO Jason Coloma disposes 1,938 Maze Therapeutics shares worth $50,388
Maze Therapeutics President R&D, CMO Harold Bernstein sells common shares worth $393,354
Reuters  ·  05-19
Maze Therapeutics President R&D, CMO Harold Bernstein sells common shares worth $393,354
LifeSci Capital Remains a Buy on Maze Therapeutics, Inc. (MAZE)
TIPRANKS  ·  05-16
LifeSci Capital Remains a Buy on Maze Therapeutics, Inc. (MAZE)
Analysts Offer Insights on Healthcare Companies: Shoulder Innovations, Inc. (SI), Maze Therapeutics, Inc. (MAZE) and PACS Group Inc (PACS)
TIPRANKS  ·  05-14
Analysts Offer Insights on Healthcare Companies: Shoulder Innovations, Inc. (SI), Maze Therapeutics, Inc. (MAZE) and PACS Group Inc (PACS)
Maze Therapeutics (MAZE) Q1 Loss Of US$24.2 Million Reinforces Bearish Earnings Narratives
Simply Wall St.  ·  05-14
Maze Therapeutics (MAZE) Q1 Loss Of US$24.2 Million Reinforces Bearish Earnings Narratives
Wedbush Sticks to Their Buy Rating for Maze Therapeutics, Inc. (MAZE)
TIPRANKS  ·  05-13
Wedbush Sticks to Their Buy Rating for Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline
TIPRANKS  ·  05-13
Maze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline
J.P. Morgan Remains a Buy on Maze Therapeutics, Inc. (MAZE)
TIPRANKS  ·  05-13
J.P. Morgan Remains a Buy on Maze Therapeutics, Inc. (MAZE)

Introduction

Company Name.
Maze Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--